Clinical trials: Arsenic Trioxide
Cancer Other Than Leukemia
Low Dose Arsenic Trioxide as a Potential Chemotherapy Protector
Many types of cancer are treated with chemotherapy drugs and/or radiation therapy. These forms of treatment, however, can also damage normal (non-cancer) cells and cause a variety of side effects.
- Trial name
- NCT01428128
- Testing
- Arsenic Trioxide
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Acute Promyelocytic Leukemia
All-trans Retinoic Acid, and Arsenic +/- Idarubicin
The goal of this clinical research study is to learn if the combination of arsenic trioxide (ATO) with ATRA and possibly idarubicin is effective in treating patients with newly-diagnosed APL.
- Trial name
- NCT00413166
- Testing
- All-Trans Retinoic Acid (ATRA), Arsenic Trioxide (ATO), Idarubicin
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- M.D. Anderson Cancer Center
Acute Myeloid Leukemia
Cytarabine in Combination With Arsenic Trioxide vs. Cytarabine Alone in Elderly Patients With Acute Myeloid Leukemia
The primary objective of this study is to determine whether low-dose cytarabine in combination with arsenic trioxide is more effective than low-dose cytarabine alone in achieving complete remission in elderly patients (≥60 years…
- Trial name
- NCT00513305
- Testing
- Arsenic trioxide, Low-dose cytarabine alone
- Where
- 12 sites in United States, Canada
- Volunteers
- 67 people
- Sponsor
- Cephalon
Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
Tretinoin and Arsenic Trioxide in Treating Patients With Untreated Acute Promyelocytic Leukemia
This phase III trial studies tretinoin and arsenic trioxide in treating patients with newly diagnosed acute promyelocytic leukemia.
- Trial name
- NCT02339740
- Testing
- Arsenic Trioxide, Cytarabine, Dexamethasone
- Where
- 174 sites in United States, Australia and 4 more
- Volunteers
- 158 people
- Sponsor
- Children's Oncology Group
Leukemia
Cytarabine (Ara-C) in Children With Acute Promyelocytic Leukemia (APL)
Several groups, especially the PETHEMA group (in their LPA96 and 99 trials), obtained low relapse rates in newly diagnosed Acute Promyelocytic Leukemia (APL) patients by combining ll-transretinoic acid (ATRA) and anthracyclines…
- Trial name
- Ara-C (NCT01191541)
- Testing
- DNR:, Ara-c
- Where
- 2 sites in China
- Volunteers
- 65 people
- Sponsor
- Xiaofan Zhu
Acute Myelogenous Leukemia
Trial of Arsenic Trioxide With Ascorbic Acid in the Treatment of Adult Non-Acute Promyelocytic Leukemia (APL) Acute Myelogenous Leukemia
This clinical research study is for patients with acute myelogenous leukemia (in short AML) that did not respond to previous treatment or unable to receive chemotherapy. Arsenic has been used as a drug for many centuries.
- Trial name
- NCT00184054
- Testing
- Arsenic Trioxide (ATO), Ascorbic Acid
- Where
- United States
- Volunteers
- 11 people
- Sponsor
- University of Southern California
Neuroblastoma
Phase II Study of Combined Chemotherapy With Arsenic Trioxide in Stage 4/M Neuroblastoma
This clinical trial aims to explore and evaluate the efficacy and safety of combined chemotherapy with arsenic trioxide for stage 4/M neuroblastoma.
- Trial name
- NCT03503864
- Testing
- Arsenic Trioxide
- Where
- China
- Volunteers
- 80 people
- Sponsor
- Yang Li
Childhood Acute Promyelocytic Leukemia With PML-RARA, Myeloid Neoplasm
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Promyelocytic Leukemia
This phase III trial is studying combination chemotherapy to see how well it works in treating young patients with newly diagnosed acute promyelocytic leukemia.
- Trial name
- NCT00866918
- Testing
- Arsenic Trioxide, Cytarabine, Diagnostic Laboratory Biomarker Analysis
- Where
- 121 sites in United States, Canada and 1 more
- Volunteers
- 106 people
- Sponsor
- Children's Oncology Group
Myeloma
Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients
Primary Objectives: 1. To evaluate the toxicity and safety of a combination of bortezomib with arsenic trioxide, ascorbic acid and high-dose melphalan in patients with multiple myeloma 2.
- Trial name
- NCT00469209
- Testing
- Trisenox (Arsenic Trioxide), Velcade (Bortezomib), Melphalan
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- M.D. Anderson Cancer Center
Lung Cancer, Cancer of Lung
Study of Arsenic Trioxide in Small Cell Lung Cancer
The purpose of this study is to study the effect of an anticancer drug, Arsenic Trioxide, in patients with small cell lung cancer who have failed at least one standard chemotherapy regimen as well as patients who are unable to…
- Conditions
- Lung Cancer, Cancer of Lung, Pulmonary Cancer, Pulmonary Neoplasms
- Trial name
- NCT01470248
- Testing
- Arsenic Trioxide
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Emory University
Carcinoma, Hepatocellular
A Phase II Protocol of Arsenic Trioxide (Trisenox) in Subjects With Advanced Primary Carcinoma of the Liver
The purpose of this study is: evaluate the safety and activity of administering arsenic trioxide (Trisenox) in the treatment of unresectable or metastatic primary liver cancer, to evaluate the qualitative and quantitative…
- Trial name
- NCT00582400
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- The University of Texas Medical Branch, Galveston
Myelodysplastic Syndrome
Cephalon Decitabine, Arsenic Trioxide and Ascorbic Acid for Myelodysplastic Syndrome
This will be an open-label, non-randomized trial pilot phase II trial open to patients with myelodysplastic syndrome. The purpose of the study is to find out if the combination of decitabine, arsenic trioxide and ascorbic acid is…
- Trial name
- NCT00621023
- Testing
- Decitabine, Arsenic Trioxide and Ascorbic Acid
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Duke University
Leukemia
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00551460
- Testing
- arsenic trioxide, gemtuzumab ozogamicin, mercaptopurine
- Where
- 192 sites in United States
- Volunteers
- 78 people
- Sponsor
- SWOG Cancer Research Network
Leukemia, Myelodysplastic Syndromes
Arsenic Trioxide and Gemtuzumab Ozogamicin in Treating Patients With Advanced Myelodysplastic Syndromes
RATIONALE: Drugs used in chemotherapy, such as arsenic trioxide and gemtuzumab ozogamicin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00274781
- Testing
- arsenic trioxide, gemtuzumab ozogamicin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- The Cleveland Clinic
Multiple Myeloma, Stem Cell Transplantation
Arsenic Trioxide With Ascorbic Acid and Melphalan for Myeloma Patients
1. To evaluate the toxicity and safety of a combination of arsenic trioxide with ascorbic acid and high-dose Melphalan in patients with multiple myeloma 2.
- Trial name
- NCT00661544
- Testing
- Arsenic Trioxide, Melphalan, Ascorbic Acid
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Carcinoma
Trisenox® in Women With Metastatic Endometrial Cancer
The primary purpose of this study is to see whether women who have already received chemotherapy for their endometrial cancer, or who have disease that has spread outside of the uterus, will respond to the drug arsenic trioxide…
- Trial name
- NRR (NCT01184053)
- Testing
- Arsenic trioxide
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer
Arsenic Trioxide in Treating Patients With Basal Cell Carcinoma
This pilot clinical trial studies arsenic trioxide in treating patients with basal cell carcinoma. Drugs used in chemotherapy, such as arsenic trioxide, work in different ways to stop the growth of tumor cells, either by killing…
- Trial name
- ATO (NCT01791894)
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Stanford University
Chronic Graft-Versus-Host Disease, Immune System Diseases
Treatment of Chronic Graft Versus Host Disease With Arsenic Trioxide
This study aims to evaluate the early chronic GvHD events (first line therapy), if the addition of arsenic trioxide to standard therapy with corticosteroids, with or without cyclosporine, will be effective in controlling chronic…
- Trial name
- GvHD-ATO (NCT02966301)
- Testing
- Arsenic Trioxide Injectable Solution
- Volunteers
- 21 people
- Sponsor
- Medsenic
Leukemia
Tretinoin and Arsenic Trioxide With or Without Idarubicin in Treating Patients With Acute Promyelocytic Leukemia
RATIONALE: Tretinoin may help cancer cells become more like normal cells, and to grow and spread more slowly. Drugs used in chemotherapy, such as arsenic trioxide and idarubicin, work in different ways to stop the growth of…
- Trial name
- NCT00528450
- Testing
- arsenic trioxide, idarubicin, tretinoin
- Where
- United States
- Volunteers
- 1 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Arsenic Trioxide in Treating Patients With Advanced Neuroblastoma or Other Childhood Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of arsenic trioxide in treating children who have advanced…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00024258
- Testing
- arsenic trioxide
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- Memorial Sloan Kettering Cancer Center